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Successful preliminary studies have encouraged a more translational phase for stem cell research. Nevertheless,
advances in the culture of human bone marrow-derived mesenchymal stromal/stem cells (hBM-MSC) and
osteoconductive qualities of combined biomaterials can be undermined if necessary cell transportation proce-
dures prove unviable. We aimed at evaluating the effect of transportation conditions on cell function, including
the ability to form bone in vivo, using procedures suited to clinical application. hBM-MSC expanded in current
Good Manufacturing Practice (cGMP) facilities (cGMP-hBM-MSC) to numbers suitable for therapy were
transported overnight within syringes and subsequently tested for viability. Scaled-down experiments mim-
icking shipment for 18 h at 4C tested the influence of three different clinical-grade transportation buffers (0.9%
saline alone or with 4% human serum albumin [HSA] from two independent sources) compared with cell
maintenance medium. Cell viability after shipment was > 80% in all cases, enabling evaluation of (1) adhesion to
plastic flasks and hydroxyapatite tricalcium phosphate osteoconductive biomaterial (HA/b-TCP 3D scaffold); (2)
proliferation rate; (3) ex vivo osteogenic differentiation in contexts of 2D monolayers on plastic and 3D HA/b-
TCP scaffolds; and (4) in vivo ectopic bone formation after subcutaneous implantation of cells with HA/b-TCP
scaffold into NOD/SCID mice. Von Kossa staining was used to assess ex vivo osteogenic differentiation in 3D
cultures, providing a quantifiable test of 3D biomineralization ex vivo as a rapid, cost-effective potency assay.
Near-equivalent capacities for cell survival, proliferation, and osteogenic differentiation were found for all
transportation buffers. Moreover, cGMP-hBM-MSC transported from a production facility under clinical-grade
conditions of 4% HSA in 0.9% saline to a destination 18 h away showed prompt adhesion to HA/b-TCP 3D
scaffold and subsequent in vivo bone formation. A successfully validated transportation protocol extends the
applicability of fresh stem cells involving multicentric trials for regenerative medicine.
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Introduction
Human bone marrow-derived mesenchymal stromal/stem cells (hBM-MSC) can be isolated and expanded
ex vivo under current Good Manufacturing Practice (cGMP)
conditions1 for clinical applications, including autologous
treatment of large bone defects,2 usually combining cells
with biocompatible bone-like scaffold biomaterials.3–7 To
date, research has predominantly been focused on growth
conditions for safe expansion of hBM-MSC ex vivo, with an
emerging consensus that platelet lysate (PL) from whole blood-
derived pooled platelet concentrates is a growth supplement of
choice,8–12 with growth-promoting properties exceeding com-
binations of its individual active components PDGF-BB, bFGF,
and TGF-b113 and consistency improved by pooling.14
In certain circumstances, the specialized cell production
facility may be distant from the operating theater, necessi-
tating transportation of the cGMP cellular therapy product
and current standards for short-term shipment between
laboratories vary.15 Specifically, the inherent osteogenic dif-
ferentiation potential of the hMSC should be maintained
beyond all processes, including isolation from tissues, cell
expansion, transportation, seeding on biomaterial, and im-
plantation. However, there is relatively little data regarding
the influence of transportation on the results of the preclin-
ical studies, especially with regard to functional outcomes
in vivo. Although cryopreserved hBM-MSC may retain good
bone-forming potential,16,17 shipments of frozen cells would
be impractical for operating theatre protocols involving
short-term storage and prompt use. Furthermore, adverse
reactions from cryoprotective reagents represent a compli-
cation,18 and freshly thawed hBM-MSC may have temporary
impairment of function.19
With regard to nonfrozen cell transportation conditions,
most studies assessed ex vivo viability and biomarker ex-
pression rather than in vivo function.20,21 It has been shown
that hMSC kept under brief cold storage maintained bone-
forming potential,22 but the effects of storage and shipping
under cGMP condition have not been evaluated. The via-
bility of short-term liquid-stored hBM-MSC was enhanced
by human serum albumin (HSA),20 but considerable differ-
ences between HSA batches from different manufacturers
were noted. We, thus, sought to compare transport buffers
with or without HSA, measuring their effects on cell viability,
adhesion to the scaffold, and ex vivo osteogenic differentia-
tion. Positive early indications of competent cell performance
justified subsequent implantation of xenografts to test bone-
forming potential. Ultimately, our clinical-grade procedures for
isolation, expansion, transportation, and seeding of cGMP-
hBM-MSC on osteoconductive biomaterial with prompt im-
plantation preserved good bone-forming potential.
Materials and Methods
Cell culture
hBM-MSCs from cGMP facilities; Etablissement Franc¸ais
du Sang, Toulouse (France), Institute of Clinical Transfu-
sion Medicine and Immunogenetics Ulm (Germany), and
Cell Factory (Fondazione IRCCS Ca’ Granda Ospedale Po-
liclinico) in Milano (Italy) were isolated and expanded to
single clinical doses of at least 100 · 106 cGMP-hBM-MSC.
The two-step protocol for unprocessed bone marrow cells
involved seeding at an initial density of 50,000 white blood
cells/cm2 in 300mL complete medium in CellStack
(Corning) tissue culture vessels using PL-based, animal-
serum free tissue culture medium.23 Informed consent from
all donors conformed to the Declaration of Helsinki, and
project approval by local ethical committees included test-
ing of BM donors according to the guidelines for prepara-
tion of blood products.
cGMP-hBM-MSCs passaged only once (p1) were shipped
as live cells in a transportation syringe on ice or as frozen
vials on dry ice. On arrival, live cells were used immedi-
ately, and frozen cells were stored in liquid nitrogen until
required. Thawed cells were seeded at 6· 103 cells/cm2 in
T75 flasks (Greiner Bio-One) incubated at 37C with 5%
humidified CO2 using maintenance medium (MM) consist-
ing of a-minimum essential medium (MEM) without nucle-
osides (Gibco Invitrogen), supplemented with 8% PL,24 1%
L-Glutamine (Gibco Invitrogen), 1UI/mL heparin (Sigma-
Aldrich), and 10mg/mL ciprofloxacin (HIKMA). The cGMP-
hBM-MSCs were replenished with fresh MM twice weekly
and at 80–85% confluence, they were detached using trypsin
0.05%/EDTA 0.02% (PAA Laboratories) or TrypLE (Gibco
Invitrogen). cGMP-hBM-MSCs were immunophenotypically
and functionally characterized in the cGMP facilities ensur-
ing high viability before shipping (data not shown).
Scaffold biomaterial
A biphasic composite calcium phosphate scaffold biomate-
rial made of 20% hydroxyapatite and 80% b-tri-calcium
phosphate (HA/b-TCP) was supplied as granules of 1–2mm
diameter with an average pore size of 300mm and manu-
factured according to ISO-13485 certification (Biomatlante SA).
Comparative analysis of transportation conditions
To pragmatically compare transportation buffers in a
controlled environment, p1 cGMP-hBM-MSC were thawed
and expanded in MM, harvested and re-suspended at
20 · 106 cells/mL of transportation buffer in a 5mL syringe
with void air removed, and kept at 4C for 18 h, mimicking
transportation from cGMP facility to hospital. The trans-
portation buffers tested were MM (control), 0.9% normal
saline (NS) 308mOsm/L, and pH-7.0 (S.A.L.F. SpA; Labor-
atorio Farmacologico) with 4% v/v HSA or NS alone. The
HSA concentration selected (4% w/v) was equivalent to
580 mM representing a mid-range value of albumin in plasma
that typically ranges from 510 to 750 mM.25 We compared
HSA from two manufacturers: HSA#1 (Kedrion) and HSA#2
(CSL Behring). After the mimicked shipment, cells from the
transportation syringe were portioned into aliquots for ex
vivo and in vivo assays (Fig. 1i–v). For full-scale shipment,
100 · 106 freshly harvested cGMP-hBM-MSC were washed in
saline solution, suspended in 5mL NS supplemented with
4% HSA solution, and packed in a sterile luer lock 20-mL
syringe (B. Braun). Cells were shipped within 18 h from Ulm
to Nantes via overnight express courier.
Viability
Cell viability before and after transportation conditions
was assessed by propidium iodide (PI; Sigma-Aldrich) up-
take and quantified by flow cytometry.26 Briefly, 5 · 104 cells
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were incubated with 50mg/mL PI for 30min on ice-deter-
mining positivity with an FACSCalibur (BD Biosciences)
instrument according to manufacturer’s instructions.
Cellular adhesion to 3D scaffold biomaterial
cGMP-hBM-MSC adhesion to HA/b-TCP scaffold was
assayed by adding 8· 105 cells in 100 mL buffer within an
upright 1-mL syringe preloaded with 20 scaffold granules
(&20mg) (Fig. 1B) using an inverted sterile eppendorf tube
lid during incubation at 37C for 1 h in a humidified 5%-CO2
incubator, whereby cells settled under gravity. Subsequently,
the percentage of viable cells that remained suspended in the
buffer was counted using 0.4% Trypan blue dye (Biochrom).
Scaffold-bound cells were stained using crystal violet buffer
(Sigma-Aldrich) (0.04% w/v in 100% methanol) and visual-
ized under bright field illumination at 2.5 · magnification
with an Axioskop-Observer-1 microscope (Zeiss) using an
Axiocam camera and Axiovision-4.8.2 software to evaluate
the percentage of scaffold surface area covered by blue
stained cGMP-hBM-MSC. Samples were scored according to
a predetermined incremental scale (Fig. 2) ranging from
0 =no adherent cells, to 5 = over 70% covered. An adhesion
assay control used freshly detached cGMP-hBM-MSC with-
out previous exposure to transportation conditions. All ex-
periments were performed in triplicate.
Three-dimensional scaffold repopulating potential
of cGMP-hBM-MSC
Colonization of the scaffold by cells stored at 4C in the
various transportation buffers was measured by a one-step
growth assay 6 days after keeping the scaffold under MM
growth conditions at 37C in a 5% CO2 humidified incuba-
tor. For better details, 4· 104 cGMP-hBM-MSC cells sus-
pended in 5mL of transportation buffer were seeded per
single scaffold granule in a 96-multiwell plate (MW) round-
bottom ultra-low attachment (ULA) surface (Corning) and
promptly incubated in a controlled atmosphere (5% CO2,
37C) for 1 h before adding 100 mL MM. Scaffold-bound cells
were visualized using crystal violet stain and quantified ac-
cording to the predetermined scoring reference (Fig. 2).
As a further control, the post-transportation proliferative
potential of cGMP-hBM-MSC monolayers was assayed by
seeding 6000 cells/cm2 in MM into 12-well 12-MW (Greiner
Bio-One) incubated at 37C in a 5% CO2 humidified
FIG. 1. Overview of experiments. hBM-MSC harvested from three independent donors at the cGMP facilities were har-
vested and maintained for 18 h at 4C in syringes according to the MM control and three transportation conditions shown.
After 18 h, the cells from each syringe were analyzed to assess cell quality with regard to (i) viability; (ii) adhesion to a 3D
scaffold; (iii) proliferation potential of cells kept as 2D monolayers or attached to 3D scaffold; (iv) ex vivo osteogenic
differentiation potential of cells kept as 2D monolayers or cells attached to 3D scaffold; and (v) in vivo bone formation of
cGMP-BM-MSC/HA/b-TCP xenografts analyzed after 6 weeks by histology. hBM-MSC, human bone marrow-derived
mesenchymal stromal/stem cells; cGMP, current Good Manufacturing Practice; HA/b-TCP, 20% hydroxyapatite and 80% b-
tri-calcium phosphate; MM, maintenance medium. Color images available online at www.liebertpub.com/tec
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incubator. Phase-contrast photomicrographs were taken 1
and 24h after seeding. MM was refreshed every 2–3 days,
discarding nonadherent cells, and a total viable cell count
after 6 days was used to calculate the fold increase in cell
number. All experiments were performed in triplicate.
Assessment of ex vivo osteogenic differentiation
Osteogenic differentiation potential in 2D monolayer cul-
ture and on 3D scaffold was assessed as shown (Fig. 1D). For
2D assays, hBM-MSCs were seeded at 1 · 104 cell/cm2 in
MM in 24-MW plates. For 3D assays, 1.2 · 105 BM-MSC in
15 mL of transportation buffer were seeded on three scaffold
granules in 96-MW round-bottom ULA plates as described
earlier for 1 h at 37C, 5% CO2 in a humidified atmosphere
before adding 100 mL MM. After 3 days’ equilibration, MM
was changed to osteogenic medium (OM), composed of a-
MEM-supplemented 8% PL with 10mM b-glycerophosphate
(Sigma-Aldrich), 0.1mM ascorbic acid-2-phosphate (Sigma-
Aldrich), and 10 nM Dexamethasone (Sigma-Aldrich), plus
addition of 100 ng/mL rhBMP-2 (Peprotech) from the 7th
day of induction.
After 2 weeks, osteogenically induced cultures in OM and
parallel-control cultures in MM were fixed and used to
compare three staining methods characterizing ex vivo oste-
ogenic differentiation on 3D scaffolds: For alkaline phos-
phatase, cultures were fixed with acetone/citrate solution for
30 s and then rinsed gently with distilled water. After incu-
bation with alkaline phosphatase staining solution (Sigma-
Aldrich) for 15min under dark, the cells were washed with
distilled water. The acetone/citrate solution and alkaline
phosphatase staining solutions were prepared as per man-
ufacturer’s instructions. Counterstaining with 0.04% crystal
violet (Sigma-Aldrich) dissolved in water was as described.27
For alizarin red, the cultures were washed at room temper-
ature in PBS, fixed on ice-cold methanol (100%v/v), washed
with distilled water, and stained with alizarin red S (1.5%
v/v, pH-4.2; Sigma-Aldrich) for 15min to detect calcium
precipitation.28 Stained monolayers were visualized at
10 ·magnification with an inverted Axioskop-Observer-1
microscope (Zeiss). For von Kossa staining, samples were
fixed in ice-cold methanol for 2min, then rinsed twice in
distilled water, and were incubated under a ultraviolet (UV)
lamp with silver nitrate (Sigma-Aldrich) in water.29 After
two further washes in distilled water, 3D culture samples
were counterstained with 0.02% nuclear fast red (Sigma-Al-
drich) in distilled water, rinsed, and then washed in water
for 10min. For each 2D sample, 10 high-power fields were
observed using 10 · magnification (Axioskop-Observer-1
inverted microscope; Zeiss); while for 3D cultures, 2.5 ·
high-power fields were used to obtain three to six photo-
micrographs from each sample. Digitally recorded images
analyzed by ImageJ software (National Institute of Health)
selectively quantified dark positively stained areas of organic
calcium deposits. Triplicate experiments were performed.
In vivo bone-formation assay in immune-deficient mice
After maintenance in transportation conditions for 18 h
at + 4C, 1.6·106 cGMP-hBM-MSCs in 80mL of buffer were
gently added to 40mg of 1–2mm diameter HA/b-TCP gran-
ules (&40 granules) preloaded in an upright 1mL tuberculin
syringe. Before surgical subcutaneous implantation into dorsal
sites of 8-week-old NOD.CB17-Prkdcscid/J mice (Charles River),30
cells were allowed to adhere to the scaffold in their respective
transportation buffers for 1h at 37C, in 5% CO2 humidified
incubator. As a control, cells grown in MM not subjected to
shipment conditions were similarly implanted in vivo. Negative
controls consisted of implantations using 40mg HA/b-TCP
incubated with MM, but without cells. The Local Ethical
Committee of the University of Modena and Reggio Emilia
approved the protocols. Briefly, animals were anesthetized with
3.6% isofluorane (Abbott), and the dorsal skin was shaved and
cleaned. Two incisions of &1 cm in length were performed on
the opposite flanks of the back, a 3-cm-long pocket was formed
by blunt dissection, and the xenograft was implanted. The
FIG. 2. Adhesion score for
cGMP-hBM-MSC on HA/b-TCP
scaffold. Representative photo-
micrographs for scaffold gran-
ules scored according to a
predetermined scale by which a
score of 0 represented no ad-
hered cells and higher scores
represented an increased per-
centage of granule surface cov-
erage by crystal violet stained
cells: 1 = less than 10%; 2= 10–
30%; 3 = 30–50%; 4= 50–70%;
5 = over 70%. The score range
0–2 was relevant for 1-h cell
adhesion, and the score range
3–5 was relevant for cell cover-
age after 6 days. Scale bar = 100
mm. Color images available on-
line at www.liebertpub.com/tec
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incisions were sutured with ethicon vicryl rapide 35-0 (Johnson
& Johnson). Six weeks post-transplantation, xenografts recov-
ered from sacrificed animals were processed for histological
studies.
Histology and immunohistochemistry
Explanted specimens were fixed with 10% buffered for-
malin for 2 days, decalcified in PBS-buffered EDTA (15%,
pH 7.4; Carlo Erba) for 14 days, and then paraffin embedded,
as similarly described for animal and human bone speci-
mens.31,32 Cut sections (3mm-thick) were deparaffinized and
stained with hematoxylin and eosin (H&E; Carlo Erba). To
quantify bone formation, areas of osteogenesis were assessed
as described.33 For each donor, triplicate sections were H&E
stained and visualized by an inverted microscope Axioskop
(Zeiss) considering 10· high-power fields. Histological an-
alyses considering bone matrix-containing embedded osteo-
cytes were used to quantify the bone tissue percentage
relative to the total area of tissue and scaffold on the slide.
Bone origin was detected by immunohistochemistry using
human-specific osteocalcin and collagen 1A2 polyclonal an-
tibodies.31 Paraffin sections (5-mm thick) were dehydrated
and stained with mouse anti-human collagen type 1A2 (1:20;
Novus Biological) and mouse anti-human osteocalcin (1:30;
Abcam) using a goat anti–mouse biotinylated secondary Ab
(1:200; Vector Laboratories) and an avidin-biotin-horseradish
peroxidase detection system (Vector Laboratories). Antigen
retrieval used proteinase k (Promega Corporation) for 30min
at room temperature, blocking nonspecific binding with
10% new-calf serum blocking reagent (Sigma-Aldrich). The
primary antibody in 0.1% bovine serum albumin (Sigma-
Aldrich) and 0.4% Triton-X (Sigma-Aldrich) was applied
overnight. After Secondary Ab (Vector Laboratories) incu-
bation and quenching, slides were incubated with Vectastain
ABC (Vector Laboratories) as per manufacturer’s instructions
with color development using NovaRED (Vector Labora-
tories). Slides were counterstained with Harris hematoxylin
(Bio Optica). Negative control specimens were stained with a
mouse isotypic IgG primary Ab (Vector Laboratories).
Stained slides were examined using a Zeiss Axioskop (Carl
Zeiss) with either a 10/0.25NA or 40/0.6NA dry objective.
Photomicrographs were acquired with an Axiocam-IcC3
color camera and Axiovision-4.8.2 software (Carl Zeiss).
Statistical analysis
All data collected were presented as means – standard
error of the mean. Statistical analysis was performed using
the paired Student’s t-test. p-Values < 0.05 were considered
statistically significant.
Results
Transportation buffers preserve fresh
cGMP-hBM-MSC viability
A direct comparison of four transport buffers with three
independent donors cGMP-hBM-MSCs revealed that under
control conditions using MM, cell death stained by PI was
equivalent to 12.13% – 1.58% of the population (Fig. 3A).
Transportation buffers invoked significantly more cell death
than MM ( p< 0.01), yet cell death remained below 20%
without enhancement of cell viability from HSA (Fig. 3B).
Given these initial viability data, we explored the interaction
of the cells with the 3D scaffold.
cGMP-hBM-MSC promptly adhered
to the 3D scaffolds
After applying cGMP-hBM-MSC to scaffold biomaterial for
1h at 37C, cells shared two fractions: (1) nonadherent cells
suspended in the shipment buffer and (2) scaffold surface-
bound cells (Fig. 4A). When using MM control conditions,
19.8%– 5% of the cells were in fraction (1) (Fig. 4B). More
nonadherent cells were found when using the transportation
FIG. 3. Viability after transportation conditions. (A) Flow
cytometric analysis of PI positivity plotted against SSC for
cells maintained under different shipment conditions, in-
cluding MM, and transportation buffers containing 4% HSA
or only NS. (B) Histogram derived from n = 3 donors indi-
cating the percentage of PI-positive dead cells after incuba-
tion for 18 h under each transportation buffer condition.
(*p< 0.05). HAS, human serum albumin; PI, propidium io-
dide; SSC, side scatter; NS, normal saline.
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buffers versus MM ( p< 0.01); ranging from 55.3%– 5.8% to
61.7%– 12.7% when using HSA#1 or HSA#2, respectively, and
44.5%– 5.7% when using NS. The nonadherent cell viability
after 1 h was highest for cells stored in MM (90.3%– 1.9%).
Notably, the corresponding nonadherent cell viability was
significantly greater for the NS only transport buffer
(86.4%– 1.3%) than either NS+ 4% HSA#1 (76.2%– 3%;
p< 0.05) or NS+ 4% HSA#2 (73.9%– 3.4%; p< 0.05).
The adhesion score was referenced to assess the fraction (2)
viable cells stringently adhered to the 3D scaffold after 1 h of
incubation and crystal violet staining. Under MM conditions,
the adhesion score was 1.44– 0.5. Significantly less cell adhe-
sion was observed with NS-only transport buffer (1.16– 0.1;
p< 0.01), nonetheless more than seen using either HSA#1
(0.91– 0.1; p< 0.01) or HSA#2 (0.82– 0.1; p< 0.05) (Fig. 4C).
Compared with the faint HA/b-TCP scaffold background
staining (Fig. 4D, E), dark blue-stained cells were clearly dis-
cernible for a reference-scale comparison. The average cell ad-
hesion score obtained with HSA#1 (Fig. 4C, H) was only 57%
( p< 0.05) of that seen with MM (Fig. 4C, F), while the NS
transportation buffer achieved 81% (Fig. 4C–I; p< 0.01) of the
MM adhesion score. Thus, with regard to a prompt and robust
cGMP-hBM-MSC adhesion capacity, NS transport buffer con-
ditionsmet themetrics desired for an operating theater context.
cGMP-hBM-MSCs proliferated in 2D culture
and efficiently repopulated 3D scaffolds
Beyond viability and adhesion, post-transportation con-
dition cells showed equivalent proliferative potential when
seeded as 2D monolayers, averaging a 13.5-fold population
increase in 6 days (Fig. 5A). Similarly, all cGMP-hBM-MSC
seeded on HA/b-TCP granules colonize their surface. Con-
trol cells in MM reached a score of 3.32 – 04, similarly
achieved using HSA-based buffers, while cGMP-hBM-MSC
stored in NS transportation buffer had lower scores (Fig. 5B;
FIG. 4. Cell adhesion to a 3D scaffold
under gravity for 1 h. Photo-
micrograph of upright 1mL syringe
containing scaffold granules seeded
with cells in 200 mL of shipment buffer
after 1 h. (A) The solid and liquid
phases were co-analyzed for n = 3 do-
nors in each of the four shipment
buffers to determine (B) the percent-
age of viable (shaded columns) or
nonviable (unshaded columns) non-
adherent cells in the supernatant and
(C) the scaffold cell adhesion score (*p,
**p, xp < 0.05). (D–I) Representative
photomicrographs comparing (D) un-
stained scaffold; (E) crystal violet
stained scaffold; (F-I) scaffolds stained
after 1 h to show attachment of cells
that had been kept for 18 h at 4C in
shipment buffers consisting of (F)MM;
(G) saline with 4% HSA#1; and (H)
saline with 4% HSA#2, (I) NS. (D-I)
Scale bar = 100 mm. Color images
available online at www.liebertpub
.com/tec
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2.14 – 0.4; p < 0.05). Thus, proliferative potential was main-
tained after early adhesion regardless of the shipment buffer
used with cells repopulating over 50% of the scaffold surface
(adhesion score 2) after 6 days in culture (Fig. 5C–F).
cGMP-hBM-MSC generated mineralized matrix
on both plastic surface and 3D scaffolds
Extending 2D MSC-plastic monolayer ex vivo osteogenic
potency assays to include consideration of 3D MSC-scaffold
adhesion, we tested three histochemical stains for detecting
the intrinsic osteogenic differentiation of 2D and 3D cultures.
Osteogenic matrix maturation-associated alkaline phos-
phatase staining was evidently more intense in differentiated
cell monolayers regardless of transportation conditions (Fig.
6A, upper panel), but intense HA/b-TCP scaffold back-
ground staining precluded proper evaluation of 3D cultures
(Fig. 6B, upper panel). Alizarin red S staining of calcium-rich
deposits, though significant in all monolayer cultures (Fig.
6A, middle panel), also suffered from high HA/b-TCP
scaffold background staining (Fig. 6B, middle panel). In
contrast, von Kossa staining of calcium phosphate provided
a clear black positive stain that was absent in control
conditions (Fig. 6A, B lower panels), enabling clear thresh-
old discrimination for image analysis software to semi-
automate quantitation (Fig. 6B, lower panel inset). In 2D,
von-Kossa-stained areas for osteogenically induced cGMP-
hBM-MSC in 2D were equivalent for all transport buffers,
regardless of HSA, and marginally greater than for cells
stored in MM ( p< 0.04; Fig. 6C). For 3D osteogenically in-
duced cGMP-hBM-MSC, von Kossa stained an average HA/
b-TCP scaffold surface area of 17.6% – 2.2% for MM, similar
to the NS-based transportation buffers, except for HSA#2
having a reduced stained area of 9.7% – 1.9% ( p < 0.05; Fig.
6D). Notably, von Kossa also revealed inter-donor hetero-
geneity, with donor#2 showing less scaffold surface area
staining, 5.4% – 1.5%, than the other two donors (24.6% –
3.9% and 21.7 – 4.7%) ( p< 0.01; Fig. 6E, F). Thus, it was
possible to measure MSC mineralized matrix production in
both 2D and 3D culture systems, providing a more com-
prehensive ex vivo assay.
Transported cGMP-hBM-MSC with HA/b-TCP
scaffolds generated ectopic bone in vivo
An in vivo xenotransplant model using sub-cutaneously
implanted cells and scaffold incontrovertibly tested the oste-
ogenic potential of cGMP-hBM-MSC post-transportation
conditions. HA/b-TCP scaffold implanted without cells con-
trolled for any inherent osteoinductive effects, revealing no
extensive bone formation, rather loosely woven extracellular
matrix and stromal cells surrounding the scaffold, sometimes
aligned adjacent to the scaffold surface to resemble the sur-
face-lining cells of normal bone tissue sections (Fig. 7A). Using
HA/b-TCP along with cGMP-hBM-MSC stored in transpor-
tation conditions, the scaffold surfaces were surrounded by
large areas of pink-stained densely woven collagen fibrils
typical of remodeled compact bone with interspersed lacunae
containing mature bone osteocytes (Fig. 7B–E and inset).
Moreover, the remodeled ectopic bone-enclosed regions were
recognizable as hematopoietic territories (Fig. 7C, E and inset),
a positive indication of good bone quality.34 In vivo bone
formation at 6 weeks, though not significantly influenced by
transportation conditions (not shown), showed inter-donor
heterogeneity for the amount of bone formed. Bone areas of
dense, pink-stained osteoid-containing osteocytes were ob-
served in tissue sections from donors #1 (28.5%– 4.1%) and #3
(22.8%– 4.5%) (Fig. 7F, H, I), while donor #2-derived MSC
demonstrated less bone formation (8.1%– 1.6%, p< 0.01; Fig.
7G, I), concordant with less ex vivo mineralization.
To verify the ontogeny of the bone-forming cells, the
presence of human bone-related proteins was investigated. A
Collagen 1A2 human-specific antibody stained osteocytes and
bone-lining cells (Fig. 7J), with the latter also showing posi-
tivity for a human-specific osteocalcin antibody (Fig. 7K), thus
verifying a robust in vivo bone-forming potential when cGMP-
hBM-MSC subjected to transportation conditions were com-
bined with HA/b-TCP osteoconductive scaffold.
FIG. 5. Proliferation poten-
tial of cells kept as 2D
monolayers or attached to 3D
scaffold. Histograms for the
fold increase in cell number
for one step time points de-
termined for cells grown as
(A) 2D monolayers on tissue
culture plastic or (B) attached
to the 3D scaffold. (C-F) Re-
presentative photomicro-
graphs of scaffolds bearing
crystal violet-stained hBM-
MSC after cells had been
kept for 18 h at 4C in the
different transportation buff-
ers indicated seeded onto the
scaffold for 1 h and then cul-
tured for 6 days in MM. Scale
bar = 100 mm. Color images
available online at www
.liebertpub.com/tec
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FIG. 6. Ex vivo osteogenic differentiation potential. Representative photomicrographs comparing three osteogenic differ-
entiation-staining methods, namely staining for ALP or calcium deposits with alizarin red or von Kossa based methods.
cGMP-hBM-MSC osteogenically induced for 2 weeks were compared with uninduced control cells grown as (A) 2D
monolayers on plastic or (B) attached to 3D scaffolds. Lower panel inset images show von Kossa staining highlighted in red
to indicate ImageJ software processed quantifiable thresholds. (C, D) Comparing different transportation buffer conditions,
the histograms show the percentage of von Kossa-positive staining of undifferentiated control cells (unshaded columns) or
osteogenically differentiated cells (shaded columns) grown as (C) 2D monolayers on plastic or (D) adhered to 3D scaffolds.
(E) Photomicrographs of von Kossa-stained scaffolds, showing donor heterogeneity for cGMP-BM-MSC osteogenically dif-
ferentiated after exposure to normal saline for 18 h. (F) Histogram for percentage area of the scaffold surface positive for von
Kossa staining as determined by ImageJ software (*, **, xp < 0.05). Scale bar= 100 mm. ALP, alkaline phosphatase. Color images
available online at www.liebertpub.com/tec
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Discussion
From preclinical studies aimed at skeletal tissue regener-
ation,2 to clinical studies involving the transplantation of
MSC with or without biomaterials,7 bone tissue engineering
shows promise. Early trials indicate that the translation of
allogeneic and autologous cell therapeutics requires con-
trolled manufacturing and delivery procedures. Given
limited starting material for autologous hBM-MSC and the
sub-optimal osteogenic performance of directly applied BM
aspirates,35 ex vivo hMSC population expansion is currently a
favored procedure adopted by cGMP cell processing
FIG. 7. In vivo bone-forming
potential. Photomicrographs of
decalcified paraffin-embedded
sections under bright field illu-
mination. (A) Comparing con-
trols of scaffold (s) without cells
versus (B) scaffold with cGMP-
hBM-MSC previously main-
tained in culture medium. Re-
gions adjacent to the scaffold
containing newly formed bone
osteoid matrix (b). Osteocytes
were observed within lacunae
(arrow). (C–E) 10 · and corre-
sponding 40 · area enlarge-
ments. Photomicrographs of
tissue sections from scaffolds
implanted with cGMP-BM-MSC
kept under shipment buffers
with (C) 4% HSA#1; (D) 4%
HSA#2; or (E) NS. Osteoid bone
(b) formed on the scaffold (s)
surrounded marrow-like regions
(m). Representative sections (F–
H) showed donor heterogeneity
with regard to the relative
amount of bone formed with (I)
the corresponding histogram
showing statistically significant
differences (*, **p< 0.05). Scale
bar= 100mm. Immunostaining
with NOVA red chromogen-
identified cells lining the newly
formed bone matrix osteoid
positive for ( J) collagen type (I)
A2 and (K) osteocalcin in con-
trast to the unstained (L) control.
Color images available online at
www.liebertpub.com/tec
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facilities. Here, we aim at verifying conditions for safe MSC
transportation to a distant hospital for immediate clinical
application, thus overcoming a need to co-localize surgical
facilities with specialized cell expansion laboratories, thereby
widening therapeutic scope.
Transportation per se is a challenging procedure requiring
careful control of cell density and temperature to maintain
integrity while conforming to important safety constraints.
Use of a clinically approved, nontoxic, and low-cell adhesion
disposable syringe as a disposable shipment tool was in
compliance with regulatory-body guidelines, simultaneously
providing a convenient vessel for immediate application of
the cells on arrival.
Considering clinical need for a minimal cell infusion vol-
ume, we tested shipment in a small volume using a relatively
high cell density suitable for promptly combining the
cells with the biocompatible scaffold material. Keeping a
cellular product at high cell density in the same buffer for a
prolonged time may foster undesirable metabolic shifts,
weakening stem cell performance.36 However, hBM-MSC
primary cultures may retain osteogenic functions more
consistently when grown as dense aggregates with higher
expression of alkaline phosphatase than dispersed single
cells.37 Furthermore, hBM-MSC ordinarily reside as cell ag-
gregates in vivo, and MSC were well maintained as dense cell
aggregates in bioreactors.38,39 Under high cell density con-
ditions in saline solution for 18 h, the hBM-MSC may ad-
vantageously undergo a mild stress similar to hypoxic
preconditioning, which could improve the regenerative ca-
pacity of hBM-MSC.40
Previous studies have indicated that cold storage of pe-
ripheral blood progenitor cells at 4C for periods of ap-
proximately 96 h was significantly better for sustaining
viability than higher ambient temperatures.41 This can also
be said for hMSC viability,20 which reportedly fell to 81%
after 24 h at 4C but was only 70% at 24C and 62% at 37C,22
thus from the outset, we chose to maintain shipment con-
ditions at 4C. Unlike this previous study, our cells origi-
nated in medium containing human PL rather than bovine
serum; however, we also observed a 20% loss of viability
after storing cGMP-hBM-MSC at low temperature for 18 h.
With some concern for such storage-associated losses, it
was important to explore the osteogenic function of the
surviving cells.
Bioengineering modifications to scaffolds for enhanced
bone formation is a rapidly evolving field,42–44 however, for
clinical-grade consistency throughout our procedures and
comparison with previous studies,45–47,34 we favored use of
HA/b-TCP scaffold to test cell attachment as an early indi-
cator of cell function. HA/b-TCP scaffold is a bioactive ma-
terial, by which ion exchange reactions with surrounding
body fluids form a biologically active carbonate apatite
surface layer, equivalent to the mineral phase in bone, pro-
moting collagen and mineral deposition from cells grown
on the scaffold surface in vivo.46 The interaction between
implant material and osteogenic cells contributes to clinical
success, and hBM-MSC show strong affinity for calcium
phosphate scaffolds that are consequently highly osseo-
conductive.48,49
We tested a ‘‘field scenario’’ that introduced the time
constraints of an operating theater, by which cells needed to
be seeded onto the scaffold for just 1 h before implantation.
Impens et al. noted in cell-adhesion studies that although half
the cells adhered to the biomaterial within 1 h, the plateau of
maximum cell adhesion was reached after 4 h.50 We also
observed nonadhered viable cells in the supernatant after 1 h,
but a 4-h adhesion period was deemed to be impractical for
surgical procedures. For the in vivo bone-formation studies,
the scaffold was implanted with accompanying supernatant;
so feasibly, some cells could subsequently attach to the
scaffold postimplantation or, nonetheless, contribute to the
engraftment as nonattached cells. Considering the spatial
uniformity of cells throughout the scaffold matrix,48 it was
important to determine whether passive rather than dynamic
loading procedures sufficed for an efficient bone-forming
outcome. For our chosen scaffold/cell ratios, microscopic
analysis revealed broadly distributed stained cells on the
seeded scaffold after 1 h. Uncomplicated loading under
gravity was advantageously convenient for procedures
within an operating theater.
In controls using MM, approximately 75% of the cells
adhered to the scaffold within 1 h; whereas using transport
buffers adhesion efficiency was about 50%. For HSA-
containing transport buffer, our choice of albumin concen-
tration reflected observations that 4% w/v HSA was more
effective than 3% or lower doses for inhibiting human en-
dothelial cell apoptosis51 and preliminary data that higher
HSA concentrations (10% or 20%) reduced cell attachment to
the b-TCP scaffold within 1 h (data not shown, Rojewski
et al., in preparation). Notably, addition of just 4% HSA to
the saline transport buffer already led to a small yet signifi-
cant reduction in the 1-h cell adhesion score and increased
the proportion of nonadhered cells, with one HSA source, in
particular increasing the number of dead floating cells. This
was contrary to expectation, as albumin, a nonglycosylated,
negatively charged protein abundant in plasma, can benefi-
cially maintain colloid osmotic pressure in plasma and
sequester hormones, fatty acids, and metabolites having anti-
inflammatory activity.52 In addition, HSA enhanced cell
viability in primary cultures of neurons due to ascribed
oxygen-scavenging activities,53 and albumin-associated lip-
ids positively influenced stem cell self-renewal.54 Thus, our
finding was surprising given that HSA could be expected to
provide a protective effect. However, HSA may simply
prevent nonspecific adsorption of dead cells on culture vessel
surfaces, artefactually allowing more dead cells to be coun-
ted. Alternatively, it is possible that co-presenting cells with
HSA in solution, which is readily adsorbed onto HA com-
posites,55 competetively interfered with cell attachment to
the scaffold surface, disrupting anchorage-dependent in-
tegrin-mediated survival signals needed to prevent anoi-
kis.56,57 Similarly, Lane et al. also reported that in the context
of hMSC in suspension, the effects of HSA from different
sources varied considerably and could reduce cell viability.20
Notably, although coating mineralized human bone allo-
grafts with freeze-dried HSA improved the adherence
and proliferation of hBM-MSC, precoating with aqueous
HSA was less effective.58 In the context of our protocol, co-
presenting aqueous HSA with cells onto fresh scaffolds may
have caused competitive binding interference rather than
enhanced adhesion. However, after 6 days ex vivo, the scaf-
fold surface area covered by cells was greater when HSA was
present; thus, over time, the beneficial effects of HSA in
protecting cell functions may have predominated. Indeed,
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further studies would be needed to determine the molecular
mechanisms underlying this observation.
With regard to testing the cGMP-hBM-MSC function of
osteogenic differentiation, we obtained data from 2D and 3D
cell culture contexts with the overall conclusion that trans-
portation buffer differences were less apparent in 2D assays
than in 3D assays. Assessment of osteogenic differentiation
using alkaline phosphatase-specific or calcium-specific aliz-
arin red S staining methods proved impractical due to a high
background stain in unseeded scaffolds. Nonetheless, the
differentiation-specific von Kossa staining method worked
well, with very low background staining of unseeded scaf-
folds. The dark von Kossa staining of mineralized cells after
osteogenic differentiation of the cells that had been main-
tained for 18 h in saline-based transportation buffers was
equivalent to that of control cells in MM. Notably, for un-
seeded scaffolds, the low von Kossa background staining
was very different from the relatively strong alizarin red S
staining of the scaffold. This seemed counterintuitive, as the
high calcium concentration of the HA/b-TCP scaffold might
be expected to cause a high background stain in both cases.
However, the two mineralization-staining methods react with
the target calcium molecules differently. Alizarin red S im-
partially reacts with calcium via its sulfonic acid and/or OH
groups to form a salt of a water-insoluble dye that selectively
stains calcium deposits at pH & 9.28 In the von Kossa reac-
tion, silver ions replace tissue calcium bound to phosphates,
with subsequent visualization of silver ions by hydroquinone
reduction to metallic silver. Puchtler et al. experimentally
confirmed differences that von Kossa himself highlighted be-
tween the yellow stain of silver nitrate reacting with pure
calcium phosphates versus black deposits in tissues, implying
that the blackening of the silver salt-protein mixture was
limited to a protein component.29 Our finding, that the black
von Kossa reaction enhanced the signal-to-noise ratio for
scaffolds coated with the osteogenically differentiated cells,
supported the view that the black stain, long considered di-
agnostic for calcium salts (phosphates and carbonates), is
more likely an organically induced by-product that, none-
theless, reflects a high local calcium concentration.
Given that ex vivo von Kossa staining need not correlate
with bone-forming potential,59 the ultimate test for cGMP-
hBM-MSC osteogenic function was to perform an in vivo
bone formation assay.45 Notably, we successfully obtained
bone formation under procedures consistently appropriate
for a clinical setting, and the cGMP-hBM-MSC were used
either directly after experiments that compared suspension
storage at 4C with different transportation buffers or di-
rectly after a genuine shipment using full-scale conditions
(data not shown, Brennan et al., in preparation). Others have
already addressed the question of whether it would be
beneficial to preincubate the cells with osteogenic factors
before implantation. For the substantial majority of hBM-
MSC strains cultured over 15 years, continuous exposure to
osteogenic differentiation factors such as dexamethasone or
ascorbic acid did not increase subsequent bone formation
under circumstances in which cells were implanted after an
equivalent adhesion to scaffold period of merely 90min,
emphasizing no need for a potentially inconvenient prior
osteogenic induction of transplanted hBM-MSC.34
In addition to bone formation in terms of dense pink-
stained osteoid harboring osteocytes in lacunae, we were re-
assured that the transplanted hBM-MSC were able to support
host hematopoietic territories. Thus, despite exposure to
shipment conditions, the ectopically implanted cGMP-hBM-
MSC retained a phenotype of bona fide multipotent skeletal
stem cells with establishment of stroma and marrow-like cell
populations alongside the new bone matrix.33
An Occam’s razor reductionist approach would suggest
that, since HSA had little beneficial influence on ultimate
outcome, 0.9%NS alone may suffice for cell shipment and
bone formation in vivo and could be recommended as the
transport medium of choice. However, the present study
indicated potential cell loss associated with the key steps of
cell transportation and predelivery attachment to the scaf-
fold, with an estimate that only 50% of the initial cell number
shipped overnight actually ended up attached to the scaffold
at the time of implantation. There may be a compromise to
be reached between procedural cell loss and maintenance of
cell viability, as alternative shipment methods and more
elaborate buffer formulations may introduce unwanted
variability and additional safety concerns. Nonetheless, al-
ternative procedures may enhance cell survival60 and effi-
ciency, leading to equivalent transplantation outcomes from
fewer cells. Although the sample size of the present study
was small, it was noteworthy that the inter-donor hetero-
geneity in osteogenic differentiation revealed by von Kossa
staining of cells on 3D scaffolds correlated well with the
subsequent inter-donor heterogeneity in bone formation.
Our cost-effective test of shipping conditions, including
quantifiable potency assay of 3D cell attachment and bio-
mineralization ex vivo, may serve as a platform to explore
procedures that further improve cGMP-hBM-MSC-mediated
therapy. Principally, our clinically compliant experiments
provided proof of concept for in vivo bone formation from
shipped cells, broadening the scope for use of centrally
produced cGMP-hBM-MSC in regenerative medicine in-
volving multicentric clinical trials.
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